NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) — Scopus BioPharma Inc. (Nasdaq: “SCPS”)a biopharmaceutical company developing transformative therapeutics for serious diseases with significant unmet medical needs and its pure-play immuno-oncology subsidiary Duet BioTherapeutics announced today that significant scientific data was presented at the 37th…^th Annual Meeting and Exhibition of the Society for Immunotherapy of Cancer (“SITC”).

SITC will take place November 8-12, 2022 at the Boston Convention and Exhibition Center in Boston, Massachusetts.

About Scopus BioPharma

Scopus BioPharma Inc. is a biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical needs. Duet BioTherapeutics, a majority-owned subsidiary of Scopus, was formed by Scopus BioPharma in September 2021 to consolidate its immunotherapy assets. These benefits include three distinctive complementary CpG-STAT3 inhibitors: RNA silencing – CpG-STAT3siRNA – (“DUET-01“); Antisense – CpG-STAT3ASO – (“DUET-02“); and DNA binding inhibitor – CpG-STAT3decoy – (“DUET-03The Company is also developing additional drug candidates and is committed to identifying additional compelling technologies for potential acquisitions, in-licensing and/or other similar transactions.

Forward-Looking Statements

This press release may contain forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks (including those set forth on the Company’s Form 10-K for the year ended December 31, 2020, as amended, and filed with the United States Securities and Exchange Commission) and uncertainties that could cause actual results of deviate from the forward-looking statements. The Company expressly disclaims any obligation or undertaking to release any updates or revisions to the forward-looking statements contained herein to reflect any…